Treatment of Pemphigus

Martin, Linda K.; Murrell, Dédée F.

doi:10.1001/archdermatol.2007.14

Cited by 18 publications

(5 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Even the RCTs that do exist have large variations in quality, are not well designed, and provide results that are often uninterpretable. 3,4 Different outcome measures and end points make direct comparisons between studies impossible. The development of definitions of disease, therapeutic response, and objective scoring systems has provided opportunities for direct comparisons between various treatment regimens in RCTs.…”

Section: Introductionmentioning

confidence: 99%

Severity score indexes for blistering diseases

Daniel

Hertl

Werth

et al. 2012

Clinics in Dermatology

View full text Add to dashboard Cite

Scoring systems are used to assess the severity of a disease and the response to treatment. The main severity scoring indexes are the Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) and the Pemphigus Disease Area Index (PDAI). They have been validated and are already used in the evaluation of pemphigus and in clinical trials. They quantify disease severity by performing a global assessment of all lesions. In recent years, other severity scoring systems have been developed for pemphigus and other autoimmune blistering diseases.

show abstract

Section: Introductionmentioning

confidence: 99%

Severity score indexes for blistering diseases

Daniel

Hertl

Werth

et al. 2012

Clinics in Dermatology

View full text Add to dashboard Cite

show abstract

“…In medicine, the ability to accurately assess disease severity is often hindered by the lack of consensus on the best scoring systems to carry out such an assessment, which can lead to inaccurate assessments of patient treatment outcome and efficacy. This is especially true for AIBDs such as pemphigus before the development of its current scoring systems, as a systematic review conducted in 2006 highlighted the lack of universally recognized outcome measures as the contributing factor to the shortage of high-quality clinical trials assessing treatments for pemphigus ( 4 ). As a response to this issue, new scoring systems for the disease have since been developed and validated, including the two most-commonly used scoring systems in pemphigus: the Pemphigus Disease Activity Index (PDAI) and Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) ( 5 , 6 ).…”

Section: Scoring Systems For Autoimmune Blistering Diseasesmentioning

confidence: 99%

Precision in treatment evaluation: importance of minimal clinically important differences (MCIDs) of outcome measures for autoimmune blistering diseases

Tseng,

Stone,

Murrell

2023

Front. Immunol.

View full text Add to dashboard Cite

Autoimmune blistering diseases (AIBDs) comprise a group of rare conditions marked by autoantibodies that specifically target intercellular adhesion molecules. Despite the progress made in comprehending the disease and the increasing number of treatment options available, there is still no definitive cure for AIBDs such as pemphigus, and it continues to have a devastating impact on those affected. The challenges in achieving new approved therapies for AIBDs are complex and multifaceted. One significant obstacle was the prior lack of validated and standardized outcome measures, which are crucial for ensuring precise comparisons between new and traditional therapies. This gap in knowledge has prompted the development of minimal clinically important differences (MCIDs), which enable efficient and reliable comparison of therapeutic outcomes between trials. MCID is defined as the minimum difference in an outcome measure that indicates a clinically significant improvement/deterioration in disease severity. Additionally, MCIDs provide a patient-centered approach to evaluating treatment efficacy, by considering whether patients experience a subjective improvement in their symptoms. Therefore, this literature review will examine the derivation and significance of MCIDs for various scoring systems in AIBDs.

show abstract

“…Since the advent of systemic corticosteroids, the mortality associated with pemphigus has reduced from 90% to 10% and is now usually related to complications of treatment [4,5]. Steroids are still the mainstay of treatment, usually used at high doses initially to get the disease under control and then in conjunction with a steroid-sparing agent for maintenance.…”

Section: Introductionmentioning

confidence: 99%

“…A recent Cochrane Review comparing treatments for pemphigus found significant heterogeneity amongst the RCTs with respect to the study designs, primary outcome measures, and therapeutic end-points. Such variation prevented the authors from performing direct comparisons and a meaningful meta-analysis [5,6]. …”

Section: Introductionmentioning

confidence: 99%

Management of pemphigus

Daniel

Murrell

2014

F1000Prime Rep

Self Cite

View full text Add to dashboard Cite

Pemphigus is an autoimmune blistering disease characterized by cutaneous and mucosal blisters and erosions. Though systemic corticosteroids have been the mainstay of treatment for pemphigus over the years, more recently research has focused on steroid-sparing agents. This review looks at the commonly used steroid-sparing agents in pemphigus and the evidence from randomized controlled trials (RCTs) supporting their use.

show abstract

Treatment of Pemphigus

Cited by 18 publications

References 14 publications

Severity score indexes for blistering diseases

Severity score indexes for blistering diseases

Precision in treatment evaluation: importance of minimal clinically important differences (MCIDs) of outcome measures for autoimmune blistering diseases

Management of pemphigus

Contact Info

Product

Resources

About